Loading…
H.R. 8857119th CongressIn committeeLatest action May 15, 2026Decoded by AI · checked against the record
The plain-language version leads. The official text is always the reference.
HR 8857 extends the Medicare price negotiation waiting period for engineered cyclic peptides from 7 to 11 years.
60-second read · 5 questions answered below
HR 8857 creates a new drug category called "engineered cyclic peptides" — small, lab-designed molecules made of amino acids that are taken by mouth, inhaled, or self-administered. Drugs that qualify under this category would wait 11 years before Medicare can negotiate their prices, instead of the current 7 years. The bill sets specific technical requirements a drug must meet to qualify for this longer protection period.
Pharmaceutical companies that manufacture engineered cyclic peptides are most directly affected, since the bill delays when the government can negotiate their prices. Medicare, which covers tens of millions of older Americans and people with disabilities, and patients who use these medications are also affected.
If price negotiation is delayed, Medicare and its enrollees could potentially pay higher prices on these drugs for a longer period of time compared to what current rules would allow. The extended timeline applies only to drugs that meet the bill's specific technical definition of engineered cyclic peptides.
AI-drafted summary. Verify it against the official text before you act on it. Read the official bill on Congress.gov
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the President.
Latest action: — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.